Compare HBIO & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBIO | BRNS |
|---|---|---|
| Founded | 1901 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.5M | 24.1M |
| IPO Year | 2000 | 2021 |
| Metric | HBIO | BRNS |
|---|---|---|
| Price | $6.11 | $0.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $18.00 | $4.00 |
| AVG Volume (30 Days) | 12.7K | ★ 38.9K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $116,176,000.00 | N/A |
| Revenue This Year | $4.77 | N/A |
| Revenue Next Year | $8.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.38 | $0.51 |
| 52 Week High | $7.50 | $2.91 |
| Indicator | HBIO | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 46.83 | 52.44 |
| Support Level | $5.91 | $0.65 |
| Resistance Level | $6.70 | $0.75 |
| Average True Range (ATR) | 0.28 | 0.05 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 9.76 | 62.94 |
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.